Evaluation of the oncologic patient before, during, and after chemotherapy

Iris Parrini, Alessandro Bonzano

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Before the beginning of the therapy, a clinician has to evaluate the extent and frequency of a proposed therapy and the patient’s risk factors. A complete cardiologic evaluation, electrocardiogram with evaluation of QTc, and an echocardiogram are the main tools of a preliminary evaluation of the candidates to chemotherapy. Additional investigations may be required in specific circumstances. Cancer patients during chemotherapy can develop several symptoms as dyspnea, palpitations, and chest pain whose differential diagnosis with other disorders is not always easy and requires specific investigation algorithms. The most widely used method for early detection of patients at high risk is echocardiography, but the measurement of cardio-specific biomarkers like troponin and NT-proBNP may be a valid diagnostic tool for early identification, assessment, and monitoring of cardiotoxicity. During therapy conduction, ECG and ECHO periodic evaluation associated to troponin and natriuretic peptides leads to different decision-making strategies.

Original languageEnglish
Title of host publicationCardiac Management of Oncology Patients: Clinical Handbook for Cardio-Oncology
PublisherSpringer International Publishing
Pages157-186
Number of pages30
ISBN (Print)9783319158082, 9783319158075
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Drug Therapy
Troponin
Electrocardiography
Natriuretic Peptides
Chest Pain
Dyspnea
Echocardiography
Decision Making
Differential Diagnosis
Therapeutics
Biomarkers
Neoplasms
pro-brain natriuretic peptide (1-76)
Cardiotoxicity

Keywords

  • BNP
  • Cardiology
  • Chemotherapy
  • Echocardiography
  • Nuclear magnetic resonance
  • Oncology
  • Radiotherapy
  • Scintigraphy
  • Toxicity
  • Troponin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Parrini, I., & Bonzano, A. (2015). Evaluation of the oncologic patient before, during, and after chemotherapy. In Cardiac Management of Oncology Patients: Clinical Handbook for Cardio-Oncology (pp. 157-186). Springer International Publishing. https://doi.org/10.1007/978-3-319-15808-2_5

Evaluation of the oncologic patient before, during, and after chemotherapy. / Parrini, Iris; Bonzano, Alessandro.

Cardiac Management of Oncology Patients: Clinical Handbook for Cardio-Oncology. Springer International Publishing, 2015. p. 157-186.

Research output: Chapter in Book/Report/Conference proceedingChapter

Parrini, I & Bonzano, A 2015, Evaluation of the oncologic patient before, during, and after chemotherapy. in Cardiac Management of Oncology Patients: Clinical Handbook for Cardio-Oncology. Springer International Publishing, pp. 157-186. https://doi.org/10.1007/978-3-319-15808-2_5
Parrini I, Bonzano A. Evaluation of the oncologic patient before, during, and after chemotherapy. In Cardiac Management of Oncology Patients: Clinical Handbook for Cardio-Oncology. Springer International Publishing. 2015. p. 157-186 https://doi.org/10.1007/978-3-319-15808-2_5
Parrini, Iris ; Bonzano, Alessandro. / Evaluation of the oncologic patient before, during, and after chemotherapy. Cardiac Management of Oncology Patients: Clinical Handbook for Cardio-Oncology. Springer International Publishing, 2015. pp. 157-186
@inbook{f8ad15f21c3a4301ab33cd323f061e90,
title = "Evaluation of the oncologic patient before, during, and after chemotherapy",
abstract = "Before the beginning of the therapy, a clinician has to evaluate the extent and frequency of a proposed therapy and the patient’s risk factors. A complete cardiologic evaluation, electrocardiogram with evaluation of QTc, and an echocardiogram are the main tools of a preliminary evaluation of the candidates to chemotherapy. Additional investigations may be required in specific circumstances. Cancer patients during chemotherapy can develop several symptoms as dyspnea, palpitations, and chest pain whose differential diagnosis with other disorders is not always easy and requires specific investigation algorithms. The most widely used method for early detection of patients at high risk is echocardiography, but the measurement of cardio-specific biomarkers like troponin and NT-proBNP may be a valid diagnostic tool for early identification, assessment, and monitoring of cardiotoxicity. During therapy conduction, ECG and ECHO periodic evaluation associated to troponin and natriuretic peptides leads to different decision-making strategies.",
keywords = "BNP, Cardiology, Chemotherapy, Echocardiography, Nuclear magnetic resonance, Oncology, Radiotherapy, Scintigraphy, Toxicity, Troponin",
author = "Iris Parrini and Alessandro Bonzano",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-3-319-15808-2_5",
language = "English",
isbn = "9783319158082",
pages = "157--186",
booktitle = "Cardiac Management of Oncology Patients: Clinical Handbook for Cardio-Oncology",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Evaluation of the oncologic patient before, during, and after chemotherapy

AU - Parrini, Iris

AU - Bonzano, Alessandro

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Before the beginning of the therapy, a clinician has to evaluate the extent and frequency of a proposed therapy and the patient’s risk factors. A complete cardiologic evaluation, electrocardiogram with evaluation of QTc, and an echocardiogram are the main tools of a preliminary evaluation of the candidates to chemotherapy. Additional investigations may be required in specific circumstances. Cancer patients during chemotherapy can develop several symptoms as dyspnea, palpitations, and chest pain whose differential diagnosis with other disorders is not always easy and requires specific investigation algorithms. The most widely used method for early detection of patients at high risk is echocardiography, but the measurement of cardio-specific biomarkers like troponin and NT-proBNP may be a valid diagnostic tool for early identification, assessment, and monitoring of cardiotoxicity. During therapy conduction, ECG and ECHO periodic evaluation associated to troponin and natriuretic peptides leads to different decision-making strategies.

AB - Before the beginning of the therapy, a clinician has to evaluate the extent and frequency of a proposed therapy and the patient’s risk factors. A complete cardiologic evaluation, electrocardiogram with evaluation of QTc, and an echocardiogram are the main tools of a preliminary evaluation of the candidates to chemotherapy. Additional investigations may be required in specific circumstances. Cancer patients during chemotherapy can develop several symptoms as dyspnea, palpitations, and chest pain whose differential diagnosis with other disorders is not always easy and requires specific investigation algorithms. The most widely used method for early detection of patients at high risk is echocardiography, but the measurement of cardio-specific biomarkers like troponin and NT-proBNP may be a valid diagnostic tool for early identification, assessment, and monitoring of cardiotoxicity. During therapy conduction, ECG and ECHO periodic evaluation associated to troponin and natriuretic peptides leads to different decision-making strategies.

KW - BNP

KW - Cardiology

KW - Chemotherapy

KW - Echocardiography

KW - Nuclear magnetic resonance

KW - Oncology

KW - Radiotherapy

KW - Scintigraphy

KW - Toxicity

KW - Troponin

UR - http://www.scopus.com/inward/record.url?scp=84943652636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943652636&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-15808-2_5

DO - 10.1007/978-3-319-15808-2_5

M3 - Chapter

SN - 9783319158082

SN - 9783319158075

SP - 157

EP - 186

BT - Cardiac Management of Oncology Patients: Clinical Handbook for Cardio-Oncology

PB - Springer International Publishing

ER -